A clinical trial enrolled its first participant testing the safety of a treatment for lymphoma, a type of cancer, using the gene-editing technique Crispr. . . . → Read More: Trial Underway for Crispr Lymphoma Therapy
|
|||||
A clinical trial enrolled its first participant testing the safety of a treatment for lymphoma, a type of cancer, using the gene-editing technique Crispr. . . . → Read More: Trial Underway for Crispr Lymphoma Therapy Venture capital financing broke global records in the second quarter of 2021, with investments in the U.S. accounting for nearly half of all dollars invested. . . . → Read More: Infographic – U.S. Leads Record Q2 Venture Funding A new enterprise discovering treatments for neurodegenerative diseases is merging with another start-up and raising $73 million its first venture round. . . . → Read More: Neuro Disease Start-Up Raises $73M in Early Funds Data collected from wearable activity trackers show extended cardiac effects in people with Covid-19 infections, in some cases for several months. . . . → Read More: Fitness Tracker Data Show Longer Covid-19 Effects Medical researchers are assessing the feasibility of a wearable device to detect advance indicators of chronic respiratory disease symptoms. . . . → Read More: Univ. Lab Testing Wearable Respiratory Monitor A clinical trial testing a nasal spray against a placebo to prevent suicide from depression enrolled its first participants considered at high risk of suicide. . . . → Read More: Trial Underway Testing Suicide-Prevention Nasal Spray Researchers developed a biodegradable polymer for printed implant scaffolds that in lab rodents maintains its shape to encourage cell and tissue growth. . . . → Read More: 3-D Printed Scaffold Helps Regrow Soft Tissue Since mid-May, NBI rose steadily, closing at 5,148 by the end of June, a gain of nine percent for the quarter and eight percent for the year. . . . → Read More: Infographic – Biotech Index Rebounds in Q2 GlaxoSmithKline and biotechnology company Alector Inc. agreed to co-develop two synthetic antibodies for treating neurodegenerative disorders. . . . → Read More: GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal A therapy designed to regenerate healthy gut microbes for treating dangerous intestinal infections is licensed for commercialization to Nestlé Health Science. . . . → Read More: Microbiome Drug Candidate Licensed in $525M Deal |
|||||
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |